Market research
3A01.F Amyris, Inc
F EUR Not available
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 17M
- P/E ratio
- Not available
- Analyst target
- 22.83
- Dividend yield
- 0.0%
- Beta
- 1.19
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 17M
- P/E ratio
- Not available
- Analyst target
- 22.83
- Dividend yield
- 0.0%
- Beta
- 1.19
About
About Amyris, Inc
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Research context
Amyris, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 3A01.F discussion.
5 years, 6 months ago
Amyris, Inc is currently in a long term uptrend where the price is trading 41.6% above its 200 day moving average.
From a valuation standpoint, the stock is 90.8% cheaper than other stocks from the Basic Materials sector with a price to sales ratio of 23.1.
Amyris, Inc's total revenue rose by 96.7% to $80M since the same quarter in the previous year.
Its net income has dropped by 39.0% to $-110M since the same quarter in the previous year.
Finally, its free cash flow grew by 72.4% to $-13M since the same quarter in the previous year.
Based on the above factors, Amyris, Inc gets an overall score of 4/5.